khimpharm
DESCRIPTION
The financial statement analysis in terms of FSA course.TRANSCRIPT
Khimpharm JSC (SANTO)
SANTOLINA has embellished the coat of arms of the town Shymkent since the 21of April 1909.
Santonin is a drug which was widely used in the past to expel parasitic worms from the body, by either killing or stunning them. Nowadays Santonin is no longer registered as a drug in most countries.
(3S,3aS,5aS,9bS)-3,5a,9-trimethyl-3a,5,5a,9b-tetrahydronaphtho[1,2-b]furan-2,8(3H,4H)-dione
(3S,3aS,5aS,9bS)-3,5a,9-trimethyl-3a,5,5a,9b-tetrahydronaphtho[1,2-b]furan-2,8(3H,4H)-dione
Brand since 1993…
Impetuously developing company, equipped with modern abroad equipment, having new modern technologies in the system of operating production and in marketing
VISION
Health is the base of any person's happiness.
Using the best technologies, the best raw materials and the best specialists we produce effective drugs of high quality at acceptable prices for strengthening people's health and improving life quality in order to give a person an opportunity to feel better, to do more and to live longer.
MISSION
20 hectare area for the main and auxiliary productionspare areas for further developmentthe necessary communicationsown boiler - house and chink5 main workshopsresearch laboratory
PRODUCTION BASE
200 denominations of generic and original remedies in the form of capsules, tablets, injection solutions in ampoules, syrups, infusions, oil, water and alcohol solutions of 24 pharmacological groups.
PRODUCT PORTFOLIO
Market share
over 50% of domestic drug production in Kazakhstan
Karaganda Pharmaceutical Plant Almaty Pharmaceutical Plant
MAIN COMPETITORS:
EXPORT TO:Uzbekistan, Kyrgyzstan, Tajikistan, Azerbaijan, Georgia, Russia, Ukraine, Armenia.
Polpharma is the majority shareholder since September 2011
New brand name
$ 85 million investment is only the "first phase"
compliance with good manufacturing practice (GMP) standards
access to over 300 products already in Polpharma's portfolio, and 400 products being developed - mainly in the gastrological, neurological and cardiology therapeutic areas - as well as oncology and biotech drugs.
KhimPharm gains the higher level of competitive advantage.
STRENGTHS
long 100-years historyhigh developed production basebroad product mixexperienced and professional specialistshigh market share
WEAKNESSES?
NO!
Access to investmentsState programState procurementCustom UnionGood manufacturing practice (GMP) standards so it can enter to international marketThe advanced training for personnel
State program for the development of the pharmaceutical industry for 2010-2014 operating in Kazakhstan: in 2014, Kazakhstan’s production of medicines will cover at least 50% of its own market.
SK-Pharmatsiya LLP is a single centralized distributor for supplying pharmaceuticals to State health institutions. The share of pharmaceuticals bought through the single distributor system will gradually increase, reaching 70-80% by 2012.
as of 2014, customs fees for pharmaceutical imports from third countries will be increased first to 5% and then in 2015 to 10%. In 2012, Kazakhstan, Belarus, and Russia will adopt documents on mutual recognition of medicine registration
CUSTOM UNION
opportunity of international expanding
ADVANCED TRAINING FOR PERSONNEL
Profitability ratios:
Items Years
2006 2007 2008 2009 2010
ROE 0,05 0,02 0,10 0,11 0,19
ROS 0,16 0,14 0,16 0,20 0,22
ROA 0,02 0,01 0,04 0,06 0,11
Gross margin rate 0,36 0,35 0,35 0,40 0,41
Liquidity ratios:
Items Years
2006 2007 2008 2009 2010
Current ratio 0,73 0,75 0,79 1,04 1,48Acid Test or Quick Ratio 0,29 0,29 0,32 0,42 0,81
Asset management ratios:
Items Years
2006 2007 2008 2009 2010
AR turnover 4,69 4,71 4,66 5,57 3,73
Days in AR 76,84 76,47 77,22 64,68 96,53
Inventory Turnover 1,78 1,87 2,12 2,29 2,78
Days in Inventory 201,86 192,04 170,11 157,55 129,43
Days in AP 87,25 91,73 32,12 28,75 65,57
Operating expenses 0,14 0,10 0,08 0,11 0,12
Sales growth 0,25 0,18 0,41 0,34
Working capital:
Working Capital Years
2006 2007 2008 2009 2010
Total LT financing 5 923 978 6 385 193 6 575 661 8 997 608 10 748 766
Total LT investment 5 594 050 5 553 493 6 117 455 5 853 987 6 470 873
Working Capital 329 928 831 700 458 206 3 143 621 4 277 893
Operating cycle needs Years
2006 2007 2008 2009 2010
Total financing of operation 618 369 748 263 320 932 369 914 999 436 Total investments in operation 2 077 431 2 326 617 2 509 905 3 035 164 4 327 967
Operating cycle needs - 1 459 062 - 1 578 354 - 2 188 973 - 2 665 250 - 3 328 531
Working Capital 329 928 831 700 458 206 3 143 621 4 277 893
Operating cycle needs - 1 459 062 - 1 578 354 - 2 188 973 - 2 665 250 - 3 328 531
Difference - 1 129 134 - 746 654 - 1 730 767 478 371 949 362
Cash flow ratios:
Items Years
2006 2007 2008 2009 2010Interest coverage ratio 1,03 2,81 2,80 1,29 6,92Capital Cost Coverage ratio 1,03 2,81 2,79 1,29 6,92Paid Debt Coverage ratio 0,07 0,29 0,28 0,36 0,69
Total Coverage Ratio 0,07 0,27 0,25 0,28 0,63
Current Liabilities Coverage Ratio 0,11 0,42 0,36 0,48 0,86
Items Years
2006 2007 2008 2009 2010Cash Flow Yield 0,54 1,89 1,21 0,88 0,80
Cash flow to sales 0,09 0,26 0,20 0,18 0,18
Cash flow to asset 0,03 0,13 0,11 0,13 0,14
Items Years
2006 2007 2008 2009 2010 Equity/Debt ratio 0,72 0,78 1,19 1,38 2,88 Equity/Assets 0,33 0,34 0,46 0,51 0,60 Debt/Assets 0,47 0,44 0,39 0,37 0,21
Debt ratios:
Leverage ratios:
Items Years
2006 2007 2008 2009 2010Financial leverage ratio (Debt/equity) 1,40 1,27 0,84 0,73 0,35
Based on everything I know about this company and its strategies, the industry and the competitors, and the external factors that will influence the company in the future, do I think this company is worth investing in for the long term? YES.
CONCLUSION